Roche has inked a deal to use Cerep’s BioPrint®, a homogenous pharmacology and ADME database. The BioPrint database is composed of three main data sets: chemical descriptors (structures and chemical information, 2-D and 3-D descriptors), in vitro profiles, and in vivo effects of tested compound.


Cerep will also generate new BioPrint® data on Roche compounds for Roche’s exclusive use. Additionally, the companies will collaborate on further development of BioPrint® and related pharmaco-informatics tools aimed at predicting as early as possible adverse drug reactions that could lead to clinical trial failures. 


 

Previous articleBayer Decides to Investigate Compugen’s Newly Discover Cancer Targets
Next articleChilean Firm CeTeCancer to Evaluate Radient’s Lung Cancer IVD for Clinical Applications